Averrhoa bilimbi L. was used as a flavour and traditional medicine to treat
inflammation, sprue, coughs, fever, gout, rectal bleeding and haemorrhoids.
Previous studies in vivo and in vitro on starfruit showed anti-inflammatory
activity but not yet known which bioactive compound for this activity. This study
aims to analyze sixty-four (64) bioactive compounds from Averrhoa bilimbi L.
as inhibitors of the cyclooxygenase-2 enzyme in silico and predict the
pharmacokinetic profile and toxicity associated with the active site of the
receptor. The enzyme cyclooxygenase-2 plays a role in the inflammatory process
by converting arachidonic acid into prostaglandins. Increased prostaglandins
will cause inflammation. This research method uses molecular docking with
YASARA, PLANTS, Marvinsketch, Pymol applications, visualization with
PLIP and ADMET prediction with pkCSM. Comparison compounds used are
diclofenac sodium and celecoxib. The results of the study showed that predicted
20 (twenty) active compared to diclofenac sodium and three (3) active compared
to celecoxib. The conclusion, erucic acid have a pharmacokinetic profile also
toxicity as very well. Erucic acid could be potential developed as a
cyclooxygenase-2 inhibitor drug.